WHO WE ARE

Management Team & Advisory Board

External Review Board

  • Marc Appel, JD, MBA
  • Colleen Cuffaro, PhD

    Principal, Canaan Partners

  • Daniel Forler, PhD

    Senior Director, Early Licensing, Bayer U.S. Pharma (LEAPs program)

  • John D. Haley, PhD

    Associate Professor, Pathology, Stony Brook University; Director, Developmental Therapeutics, Stony Brook Cancer Center; Director, Stony Brook University Proteomics Center

  • Kenton C. Hasson, PhD

    Director of Strategic Partnerships, ANGLE plc

  • Brandy Houser, PhD

    Site Head, New York, NY, Celdara Medical

  • Thomas D. Ippolito

    Vice President, Clinical and Regulatory Affairs, Chembio Diagnostic Systems, Inc.

  • Sathapana (Sam) Kongsamut, PhD

    President, Rudder Serendip LLC.

  • Jonathan Mandelbaum, PhD

    Vice President, Private Equity, OrbiMed

  • Michael E. Marino, PhD

    Manager, Drug Product Analytical Technologies, Regeneron Pharmaceuticals

  • Annie Mitsak, PhD

    Partner, Cure Ventures

  • Stephanie C. Oestreich, PhD, MPA

    Managing Director, Myeloma Investment Fund, MMRF

  • Christopher O’Donnell, PhD

    Executive Director, External Science & Innovation and Principal, Pfizer Ventures.

  • Barbara Sawitsky

    Director of Patents and Licensing, New York Blood Center

  • Tara Sharif, PhD

    Managing Director WestPark Capital, Inc.

  • Stephanie Stehman, PhD

    Sr. Director, Business Development, Spark Therapeutics, Inc.

  • James R. Tonra, PhD

    President & CSO, Seed Therapeutics

  • Heather Walsh, PhD

    Executive Director, Head of New Business Opportunities, Rx+ Business Accelerator, Astellas Pharma

  • Leigh Zawel, PhD

    Executive-in-Residence, Atlas Venture; CSO, Pheon Therapeutics

  • Peter Young, MBA

    Venture Partner
    Pappas Capital